Intellia Therapeutics has filed an 8-K with the SEC regarding its latest financial results, though the company has yet to provide specific earnings or guidance data in the initial summary.
Intellia Therapeutics filed an 8-K on 2026-11-05 disclosing Item 2.02 results of operations and financial condition, i.e. a quarterly earnings release. The filing summary contains no revenue, loss, cash or guidance figures and no exhibit content, so the direction of the price reaction cannot be judged from this text. Impact is routine-to-relevant pending the actual numbers.
The filing is an 8-K dated 2026-11-05 covering Item 2.02, Results of Operations and Financial Condition, plus Item 9.01 Financial Statements and Exhibits; the specific figures are not included in the filing summary.
The text gives no numbers, guidance or exhibit details, so it does not by itself establish whether the results were better or worse than expected.
Intellia Therapeutics, Inc. submitted an 8-K filing on November 5, 2026, to report its results of operations and financial condition. The filing includes standard disclosures under Item 2.02 and Item 9.01, though specific financial metrics, revenue figures, and guidance were not detailed in the summary.
The company filed an 8-K on November 5, 2026, regarding its results of operations and financial condition, as well as associated financial statements and exhibits.
No, the filing summary does not contain specific financial figures, revenue data, or updated guidance for the company.